Krystal Biotech GAAP EPS of $2.05 beats by $0.28, revenue of $1.1B beats by $973.46M
- Krystal Biotech press release (KRYS): Q3 GAAP EPS of $2.05 beats by $0.28.
- Revenue of $1.1B (+1024.7% Y/Y) beats by $973.46M.
- Cash, cash equivalents and investments totaled $1.2 billion as of September 30, 2026
- Product revenue, net totaled $127.3 million and $97.8 million for the three months ended September 30, 2026 and September 30, 2025, respectively.
-
Financial Guidance
($ in millions) FY 2026 Guidance Non-GAAP Research and Development (“R&D”) and Selling, General and Administrative (“SG&A”) expense(1) $155.0 - $165.0
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.